The Application Value of Spectral CT in the Accurate Staging of Liver Cancer

NCT06977399 | Not Yet Recruiting

• 1 other identifier: KYLX2025-108
• Study Type: interventional
• Target: 150
• Locations: 1 country
• Sites: 1

Brief Summary

Spectral CT was used to prospectively collect medical images and clinical data related to liver cancer, evaluate the effect of image quality in the diagnosis of liver cancer, and evaluate the application value in the accurate staging of liver cancer, so as to provide a more accurate clinical basis for diagnosis, promote the development of individualized treatment, and ultimately improve the prognosis of patients.

Conditions

Liver Cancer

Outcome Measures

Primary Outcomes (1)

• Pathological TNM staging

  Pathological examination information: The pathology results using surgery/biopsy data are the gold standard, and the depth of tumor invasion, lymph node metastasis, and distant metastasis are recorded

  1 day

Study Arms (1)

The application value of spectral CT in the accurate staging of liver cancer

EXPERIMENTAL

Prospectively collect medical images and clinical data related to liver cancer using Philips Quark CT equipment, and evaluate the diagnostic accuracy and clinical application value in the accurate staging of liver cancer.Patients diagnosed with liver cancer in Yunnan Provincial Cancer Hospital from April 2025 to May 2026 were consecutively included, and after scanning with Philips Quark CT, the TNM stage of liver cancer patients was assessed by two radiologists, and finally statistical analysis was performed.

Diagnostic Test: To explore the value of spectral CT in the diagnosis and treatment of liver cancer

Interventions

To explore the value of spectral CT in the diagnosis and treatment of liver cancer DIAGNOSTIC_TEST

The CT scan is part of the standard treatment protocol.

The application value of spectral CT in the accurate staging of liver cancer

Eligibility Criteria

• Age: 18 Years - 80 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Undergo a contrast-enhanced Quark Spectral CT scan of the lower abdomen/pelvis within 1 week before treatment.
• Age \> 18 years.
• Patients suspected of having liver cancer.
• Patients who have signed the informed consent form.

You may not qualify if:

• Severe cardiac, pulmonary, or renal insufficiency.
• Allergy to iodine-based contrast agents.
• Inability to cooperate with the CT examination.
• Poor image quality of the Quark Spectral CT scan.
• Women who are pregnant or breastfeeding.

Sponsors & Collaborators

• Yunnan Cancer Hospital: lead

Study Sites (1)

Yunnan Cancer Hospital

Kunming, Yunnan, 650118, China

Location

MeSH Terms

Conditions

Liver Neoplasms

Condition Hierarchy (Ancestors)

Digestive System Neoplasms; Neoplasms by Site; Neoplasms; Digestive System Diseases; Liver Diseases

Study Officials

• Lianhua Ye

  Ethics Committee of Yunnan Provincial Cancer Hospital

  STUDY DIRECTOR

Central Study Contacts

Xumin Liu

CONTACT

+8615974863526; 2020429055@kmmu.edu.cn

Zhenhui Li

CONTACT

+8613698736132; lizhenhui@kmmu.edu.cn

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: NA
• Masking: NONE
• Purpose: DIAGNOSTIC
• Intervention Model: SINGLE GROUP
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: May 9, 2025
• First Posted: May 18, 2025
• Study Start: June 1, 2025
• Primary Completion (Estimated): May 31, 2026
• Study Completion (Estimated): May 31, 2026
• Last Updated: May 18, 2025

Record last verified: 2025-05

Locations

CN (1)